Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics

https://doi.org/10.20996/1819-6446-2019-15-2-282-288

Full Text:

Abstract

Tactics for the management of patients with hypertriglyceridemia (HTG) is provided in the conclusion of the Advisory Board. It is demonstrated that HTG is quite prevalent in patients with excessive body weight and is an important component of residual risk. HTG creates additional conditions for the progression of atherosclerosis, and thus it is recommended to test triglyceride in patients with high, very high and extremely high cardiovascular risk. The indication for the pharmacological treatment to reduce the triglycerides concentration is their level more than 2.3 mmol/l. Statins are drugs of choice aimed to decrease the cardiovascular risk in patients with hypercholesterinemia and HTG. Fenofibrate is used to correct HTG; in case of its intolerance or if the triglyceride target level is not reached, ethyl esters of omega-3 polyunsaturated fatty acid can be used in the dosage of 2-4 g daily. In patients with triglyceride level higher than 5.6 mmol/l, fenofibrate is the main option of treatment.

About the Authors

G. P. Arutyunov

Russian Federation
Moscow


S. A. Boytsov

Russian Federation
Moscow


M. I. Voyevoda

Russian Federation
Novosibirsk


V. S. Gurevich

Russian Federation
St. Petersburg


O. M. Drapkina

Russian Federation
Moscow


V. V. Kukharchuk

Russian Federation
Moscow


A. I. Martynov

Russian Federation
Moscow


I. V. Sergiyenko

Russian Federation
Moscow


M. V. Shestakova

Russian Federation
Moscow


A. S. Aliyeva

Russian Federation

St. Petersburg



N. M. Akhmedzhanov

Russian Federation
Moscow


M. G. Bubnova

Russian Federation
Moscow


А. S. Galyavich

Russian Federation
Kazan


I. G. Gordeyev

Russian Federation
Moscow


M. V. Ezhov

Russian Federation
Moscow 


Yu. A. Karpov

Russian Federation
Moscow


V. O. Konstantinov

Russian Federation
St. Petersburg


S. V. Nedogoda

Russian Federation
Volgograd


E. M. Nifontov

Russian Federation
St. Petersburg


Ya. A. Orlova

Russian Federation
Moscow


A. V. Panov

Russian Federation
St. Petersburg


S. A. Sayganov

Russian Federation
St. Petersburg


V. V. Skibitskiy

Russian Federation
Krasnodar


E. I. Tarlovskaya

Russian Federation
Nizhniy Novgorod


S. A. Urazgildeyeva

Russian Federation
St. Petersburg


Yu. Sh. Khalimov

Russian Federation
St. Petersburg


References

1. WHO newsletter. Cardiovascular diseases [cited by Apr 20, 201 9]. Available from: https: //www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

2. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(1 5):1 503-1 6. doi:10.1056/NEJMoa070829.

3. Chung S.C., Hlatky M.A., Faxon D., et al. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol. 2011 ;58(8):810-9. doi:10.1016/j.jacc.2011.05.020.

4. Frye R.L., August P., Brooks M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-1 5. doi:10.1056/NEJMoa0805796.

5. Henderson R.A., Pocock S.J., Clayton TC., et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy, J Am Coll Cardiol. 2003;42(7):1 1 61 -70. doi:10.1016/S0735-1097(03)00951-3.

6. Poole-Wilson P.A., Lubsen J., Kirwan B.A., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849-57. doi:10.1016/S0140-6736(04)16980-8.

7. Steg P.G., Greenlaw N., Tardif J.C., et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33(22):2831 - 40. doi:10.1093/eurheartj/ehs289.

8. Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euroheart survey of stable angina: prospective observational study. BMJ. 2006;332(7536):262-7.doi:10.1136/bmj.38695.605440.AE.

9. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(1 1):1 1 97-206. doi:10.1001/jama.297.11.1197.

10. Taylor J. SWEDEHEART: Sweden's new online cardiac registry, the first of its kind. Eur Heart J. 2009;30:21 65-73.

11. Castelli W.P. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1 992;70(19):3H-9H. doi:10.1016/0002-9149(92)91083-G.

12. Barter P., Gotto A. M., LaRosa J. C., et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. N Engl J Med. 2007;357:1301-10. doi:10.1056/NEJMoa064278.

13. Carey VJ., Bishop L., Laranjo N., at al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;1 06(6):757-63. doi:10.1016/j.amjcard.2010.05.002.

14. Aguiar C., Alegria E., Bonadonna R.C., et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1 -12. doi:10.1016/S1567-5688(15)30001-5.

15. Grundy S.M., Becker D., Clark L.T., et al. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. September 2002. NIH Publication No. 02-5215.

16. Yezhov M.V., Sergienko I.V., Aronov D.M., et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis, Atherosclerosis and Dyslipidemia. 2017;3:5-22 (In Russ.)

17. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272.

18. Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinology. 2013;2(8):655-66. doi:10.1016/S2213-8587(13)70191-8.

19. Ghandehari H., Kamal-Bahl S., Wong N.D. Prevalence and extent of dyslipidemiaand recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156 (1 ):112-9. doi:10.1016/j.ahj.2008.03.005.

20. Gitt A.K., Drexel H., Feely J., et al. DYSIS Investigators. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;1 9(2):221 -30. doi :10.1177/1741826711400545.

21. Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176 (8):1 1 13-20. doi:10.1503/cmaj.060963

22. Aguiar C. Atherogenic dyslipidaemia: the importance of its management in high risk patients. Clin Invest Arterioscl. 2017;29(Supl 2):2-8.

23. Reaven G.M., Chen YD.L., Jeppesen J., et al. Insulin resistance and hypertriglyceridemia in an individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141.

24. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride Coronary Disease Genetics, Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1 634-9. doi:10.1016/S0140-6736(10)60545-4.

25. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-33. doi:10.1001/jama.294.3.326.

26. International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidaemia. J Clin Lipidol. 2014;8(1 ):29-60.

27. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362:1 563-74. doi:10.1056/NEJMoa1001282.

28. Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:1 1 -22. doi:10.1056/NEJMoa1812792.

29. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;1 1(2):89-94. doi:10.1111/j.1463-1326.2008.00917.x.

30. Fruchart J.C., Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006;42(1):39-64. doi:10.1358/dot.2006.42.1.963528.

31. Keating G.M., Croom K.F Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67( 1 );121 -53. doi:10.2165/00003495-200767010-00013.

32. Feher M.D., Caslake M., Foxton J., et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev. 1 999;1 5:395. doi:10.1002/(SICI)1 520-7560(1 9991 1/1 2)15:6<395::AID-DMRR65>3.0.CO;2-N.

33. Baigent C., Blackwell L., Emberson J., et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. doi:10.1016/S0140-6736(10)61350-5.

34. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97. doi:10.1056/NEJMoa1410489.

35. Mark L., Dani G., Fazekas O., et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Curr Med Res Opin. 2007;23(7):1 541 -8. doi:10.1185/030079907X199817.

36. DAIS investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-1 0. doi:10.1016/S0140-6736(00)04209-4.

37. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi :10.1016/S0140-6736(05)67667-2.

38. Wierzbicki A.S. FIELD of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract. 2006;60(4):442-9. doi:10.1111/j.1368-5031.2006.00882.x.

39. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;1 1 3:2363-72. doi:10.1161/CIRCULATIONAHA.106.174516.

40. Ballantyne C.M., Jones P.H., Kelly M.T., et al. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011;25:59-67. doi:10.1007/s10557-011-6280-1.

41. Roth E.M., McKenney J.M., Kelly M.T., et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs. 2010;10(3):175-86. doi :10.2165/11533430-000000000-00000.

42. Farnier M., Ducobu J., Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol. 2010;106:787-92. doi:10.1016/j.amjcard.2010.05.005.

43. Farnier M., Steinmetz A., Retterstol K., et al. Fixed-dose combination fenofibrate/ pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther, 2011 ;33(1 ):1-12. doi:10.1016/j.clinthera.2011.02.006.

44. Jones P.H., Cusi K., Davidson M.H., et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2010;1 0(2):73-84. doi:10.2165/10061630-000000000-00000.


For citation:


Arutyunov G.P., Boytsov S.A., Voyevoda M.I., Gurevich V.S., Drapkina O.M., Kukharchuk V.V., Martynov A.I., Sergiyenko I.V., Shestakova M.V., Aliyeva A.S., Akhmedzhanov N.M., Bubnova M.G., Galyavich А.S., Gordeyev I.G., Ezhov M.V., Karpov Y.A., Konstantinov V.O., Nedogoda S.V., Nifontov E.M., Orlova Y.A., Panov A.V., Sayganov S.A., Skibitskiy V.V., Tarlovskaya E.I., Urazgildeyeva S.A., Khalimov Y.S. Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics. Rational Pharmacotherapy in Cardiology. 2019;15(2):282-288. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-2-282-288

Views: 255


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)